Aura Biosciences, Inc.: financial statements

AURANASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$6.87

November 20, 2026Market cap $715M

What Ploutos Investor adds for Aura Biosciences

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 6 fiscal years, from 2020
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

2023–2025 fiscal years

Click a line to see it on the chart.

Operating income

Line202320242025Average a year
Operating income -$85M-$96M-$113M
Net income -$76M-$87M-$106M
Earnings per share -$1.93-$1.75-$1.76
Earnings per share, basic -$1.93-$1.75-$1.76

Financial statements

AURA's revenue, profits and cash flows from 2020 to 2022, 3 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

$17M Leases0.0% Effective tax rate

Leases

Dec 31, 2025

Operating leases

$17M

Finance leases

–

Average discount rate
10.7%
Lease cost for the year
$3.5M

The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing

Operating lease payments by year

Lease liability by year

Leases

AURA's leases from 2021 to 2022, 2 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

From the statutory to the effective tax rate, 2025

Dec 31, 2025

Statutory rate

21.0%

Effective rate

0.0%

-21.0 pts

The company paid 0.0% in tax on its profit, 21.0 points below the US federal rate (21.0%). Below, the reasons it gives.

The lines the company states do not reach its effective rate, so we do not show them. Both rates are the filing's. The filing

Effective tax rate by year

Effective tax rate by year

The tax rate AURA paid on its profit, from 2020 to 2022, 3 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

The metrics a company reports about itself (users, stores, subscribers) are read for S&P 500 companies only.

The full analysis

What do Aura Biosciences's filings show?

These are Aura Biosciences's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about AURA's financials

Didn't find what you were looking for?

Ask us
How much debt does AURA have?

On December 31, 2025 Aura Biosciences had total assets of $169M, debt of – and shareholders' equity of $137M.

How much free cash flow does AURA have?

In fiscal 2025 Aura Biosciences had cash from operations of -$85M and spent $447.0K on capital expenditure, leaving -$85M of free cash flow.

Where are the figures from?

From Aura Biosciences, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.